Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Angiotensins
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
B7-H1 Antigen
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Humans
Immune Checkpoint Inhibitors
Lung Neoplasms
/ drug therapy
Prescriptions
Programmed Cell Death 1 Receptor
/ therapeutic use
Prospective Studies
Retrospective Studies
angiotensin-converting enzyme
immune checkpoint
macrophages
non-small cell lung cancer
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
27 10 2020
27 10 2020
Historique:
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension and congestive heart failure. Preclinical data show that ACE plays a role on both innate and adaptive immune responses. Since interactions between ACE inhibitors and immune checkpoint inhibitors (ICIs) have not been reported, the aim of this study is to investigate the influence of ACE inhibitors on non-small cell lung cancer (NSCLC) patients treated with programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. We conducted a retrospective cohort analysis of NSCLC patients treated with PD-1/PD-L1 inhibitors. Clinical and co-medication data as well as tumor biopsies were collected. Groups were defined according to patients' co-medications at the time of ICI initiation. Among the 178 patients included, 22 (13.1%) received ACE inhibitors. While baseline characteristics were similar in both groups, ACE inhibitors group had a shorter median PFS (Progression-Free Survival) compared to the control group: 1.97 vs. 2.56 months,
Identifiants
pubmed: 33178495
doi: 10.1080/2162402X.2020.1836766
pii: 1836766
pmc: PMC7595630
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Angiotensins
0
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1836766Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interest.
Références
Cell Cycle. 2011 May 1;10(9):1363-9
pubmed: 21441775
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cancers (Basel). 2019 Feb 10;11(2):
pubmed: 30744168
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Hypertension. 2014 May;63(5):951-7
pubmed: 24516103
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Clin Cancer Res. 2019 Oct 1;25(19):5743-5751
pubmed: 31040150
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancers (Basel). 2018 Mar 14;10(3):
pubmed: 29538329
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Clin Cancer Res. 2006 Jul 1;12(13):4095-102
pubmed: 16818710
Br J Cancer. 2017 Apr 25;116(9):1141-1147
pubmed: 28324889
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Cancer J. 2018 Jan/Feb;24(1):15-19
pubmed: 29360723
Nat Immunol. 2011 Oct 02;12(11):1078-85
pubmed: 21964607
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151303
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Genome Med. 2018 Nov 29;10(1):93
pubmed: 30497521
Am J Physiol Regul Integr Comp Physiol. 2013 Aug 1;305(3):R205-15
pubmed: 23739345
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
Cancer Res. 2017 Oct 15;77(20):5639-5651
pubmed: 28819022
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Clin Cancer Res. 2019 Feb 1;25(3):957-966
pubmed: 30154227
J Biol Chem. 2019 Mar 22;294(12):4368-4380
pubmed: 30670595
Cell. 2016 Apr 7;165(2):276-87
pubmed: 27058662
J Am Coll Cardiol. 2014 Jun 17;63(23):2491-2502
pubmed: 24613322
J Thorac Oncol. 2020 Feb;15(2):288-293
pubmed: 31622733
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
J Immunother Cancer. 2019 Nov 6;7(1):287
pubmed: 31694714
Clin Lung Cancer. 2019 Mar;20(2):88-96.e6
pubmed: 30425022
Blood. 2017 Jul 20;130(3):328-339
pubmed: 28515091
J Thorac Dis. 2018 Dec;10(12):6636-6652
pubmed: 30746209
Inflamm Res. 2013 Sep;62(9):823-34
pubmed: 23868500
J Hepatol. 2019 Apr;70(4):710-721
pubmed: 30572006
Nature. 2012 Sep 13;489(7415):220-30
pubmed: 22972295
Am J Pathol. 2007 Jun;170(6):2122-34
pubmed: 17525278
ESMO Open. 2019 Feb 27;4(1):e000457
pubmed: 30964126
Sci Rep. 2017 Aug 25;7(1):9417
pubmed: 28842601
Br J Cancer. 2018 Oct;119(8):950-960
pubmed: 30318514
Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2856-64
pubmed: 21979434
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Nat Rev Nephrol. 2018 May;14(5):325-336
pubmed: 29578208
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
Ann Oncol. 2019 Oct 1;30(10):1572-1579
pubmed: 31268133